IS Pharma, a speciality pharmaceutical company that develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology, has launched Aquoral oral spray in the UK.
Aquoral oral spray that is indicated for the lubrication and protection of the oral mucosa in xerostomia (dry mouth), a common side-effect of chemotherapy and radiotherapy.
The launch adds another product to the oncology products commercial portfolio.
Other products in the portfolio include: Aloxi – for the prevention of chemotherapy induced nausea and vomiting, Episil – for the pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.
IS Pharma CEO Tim Wright said that the commercial launch of Aquoral in the UK is a further step in the successful implementation of our strategy of building and maintaining a fast growing and profitable specialist pharmaceutical company through the acquisition and growth of specialist hospital medicines.